LAURUSLABS
LAURUSLABS
LAURUSLABS · NSE
₹2,294.6
-0.49% (-₹11.4)
Prev. close
₹2,306
Volume
8,79,357
Delivery %
51.9%
As of
20 Nov 2026
Price history
Chandan Taparia · Motilal Oswal Financial Services Ltd · 26 Oct 2026, 17:39 IST
“Recommends buying Laurus Labs with a target price of ₹2,180 and a stop-loss of ₹1,990. The stock negated lower lows, bounced from its 50 DEMA, formed a bullish Marubozu candle, and shows an improving price structure with RSI nearing a bullish crossover.”
Entry ≈ ₹2,075 (first trade after call)Target ₹2,180 (+5.1%)Stop ₹1,990 (-4.1%)R:R ~1.2:1Target hit · 28 Oct 2026
Analyst sentiment
Analysts lean bullish
2 analyst stances · last 90 days · one per analyst
Trackable
2 · 2 bull / 0 neutral / 0 bear
Long-Horizon
none in range
Commentary
none in range
Trackable = verdict-bearing calls · Long-Horizon = 1yr+ horizon, verdict pending · Commentary = context, not graded
| Call | Analyst | Instrument | Verdict | Actions | |||
|---|---|---|---|---|---|---|---|
| “For Laurus Labs, Taparia is bullish for the week, setting a target of ₹2,600 and a stop‑loss at ₹2,380. He highlights th…” | Chandan TapariaMotilal Oswal Financial Services Ltd | Laurus Labs | PENDING | ||||
| “Recommends buying Laurus Labs with a target price of ₹2,180 and a stop-loss of ₹1,990. The stock negated lower lows, bou…” | Chandan TapariaMotilal Oswal Financial Services Ltd | Laurus Labs | HIT | ||||
“Recommends buying Laurus Labs with a target price of ₹2,180 and a stop-loss of ₹1,990. The stock negated lower lows, bounced from its 50 DEMA, formed a bullish Marubozu candle, and shows an improving price structure with RSI nearing a bullish crossover.” How this call is judged A call is judged on closing prices only: a close at its target is a hit and a close at its stop is a miss. A call that states an entry starts at the first close that reaches it; if none does in the days allowed, it was never triggered, is not graded and counts toward no hit rate. No time frame is stated and the call gives both a target and a stop, so it is tracked until a close reaches one of them (rule H6): the target first is a hit, the stop first a miss, and until then it stays open. No entry price is stated, so the call starts at the first close after it was published. Target ₹2,180, stop ₹1,990, as stated. No time frame is stated, so it is tracked until a close reaches ₹2,180 or ₹1,990: there is no fixed window. The target ₹2,180 was reached on a close before the stop ₹1,990. Hit. The grader's working: R4 TARGET_CALL: entered ₹2142 on 2026-10-27 (next trading session's close); target ₹2180 reached at close ₹2181.9 on 2026-10-28. No time frame is stated and the call gives both a target and a stop, so it is tracked until a close reaches one of them (rule H6): the target first is a hit, the stop first a miss, and until then it stays open. (21 Nov 2026) | |||||||
| “Bullish on Laurus Labs, recommending a buy with a target of ₹2,100 and a stop loss at ₹1,920. The stock is in a strong u…” | Chandan TapariaMotilal Oswal Financial Services Ltd | Laurus Labs | HIT | ||||
| “Bullish on Laurus Labs, recommending a buy with a target price of ₹2,130 and a stop loss of ₹1,950. The stock is in a st…” | Chandan TapariaMotilal Oswal Financial Services Ltd | Laurus Labs | HIT | ||||
| “Bullish on Laurus Labs, recommending a buy with a target price of ₹2,050 and a stop loss of ₹1,890. The stock is in an o…” | Chandan TapariaMotilal Oswal Financial Services Ltd | Laurus Labs | HIT | ||||
| “Bullish on Laurus Labs, recommending a buy at ₹1867 with a target of ₹1900 and a stop loss at ₹1840.” | Vaishali ParekhPrabhudas Lilladher | Laurus Labs | NOT TRIGGERED | ||||
| “Bullish on Laurus Labs, recommending a buy at CMP Rs 1,938 with a target of Rs 2,050 and a stop loss of Rs 1,880. The st…” | Chandan TapariaMotilal Oswal Financial Services Ltd | Laurus Labs | MISS | ||||
| “Bullish on Laurus Labs, recommending a buy with a target price of ₹2,050 and a stop loss of ₹1,870. The stock has shown …” | Chandan TapariaMotilal Oswal Financial Services Ltd | Laurus Labs | MISS | ||||
| “Within the pharmaceutical sector, Nischal Maheshwari favors the CDMO sub-segment, which he sees growing very rapidly. La…” | Nischal MaheshwariIndependent | Laurus Labs Limited | HIT | ||||
| “Recommends buying Laurus Labs at ₹1030 for an intraday target of ₹1060, with a stop loss at ₹1005.” | Vaishali ParekhPrabhudas Lilladher | Laurus Labs | MISS | ||||
| “Recommends buying Laurus Labs shares at ₹1,031, with a stop-loss at ₹995 and a target price of ₹1,103. The stock shows s…” | Sumeet BagadiaChoice Equity Broking | Laurus Labs | HIT | ||||
| “Bullish on Laurus Labs, recommending a buy with a target price of ₹1,060 and a stop loss at ₹970. The stock is in an ove…” | Chandan TapariaMotilal Oswal Financial Services Ltd | Laurus Labs | HIT | ||||
| “Bullish on Laurus Labs, recommending a buy above ₹1004 with a target of ₹1029 and a stop loss at ₹990 for intraday tradi…” | Raja VenkatramanNeoTrader | Laurus Labs | HIT | ||||
| “Recommends buying Laurus Labs at ₹1,001, targeting ₹1,071 with a stop loss at ₹966. The stock exhibits strong bullish mo…” | Sumeet BagadiaChoice Equity Broking | Laurus Labs | HIT | ||||
| “Recommends buying LAURUSLABS above ₹965 with a stop loss at ₹940 and an intraday target of ₹1,000 for October 31. This i…” | Raja VenkatramanNeoTrader | Laurus Labs | HIT | ||||
| “Bullish on Laurus Labs (LAURUSLABS), recommending a buy above ₹965 with a target of ₹1000 and a stop loss at ₹940 for in…” | Raja VenkatramanNeoTrader | Laurus Labs | HIT | ||||
| “Recommends buying Laurus Labs above ₹965 with a stop loss at ₹940 and an intraday target of ₹1,000. This call is for Oct…” | Raja VenkatramanNeoTrader | Laurus Labs | HIT | ||||
| “Recommends buying Laurus Labs at ₹940, setting a stop loss at ₹907 and targeting ₹1,006. The stock exhibits strong bulli…” | Sumeet BagadiaChoice Equity Broking | Laurus Labs | NOT TRIGGERED | ||||
| “Maintains a 'Buy' rating on Laurus Labs with a target price of ₹1,085, based on the company's strategic shift towards a …” | Choice Institutional Equities AnalysisChoice Institutional Equities | Laurus Labs | HIT | ||||
| “Reiterated a 'Buy' rating on Laurus Labs with a target price of ₹1,110, citing a better-than-expected Q2 FY26 performanc…” | Motilal Oswal AnalysisMotilal Oswal Financial Services | Laurus Labs | HIT | ||||
| “Bullish on Laurus Labs, which is on the verge of a breakout at 944 levels, supported by huge rising volumes. The stock i…” | Rajesh PalviyaAxis Securities | Laurus Labs | HIT | ||||
| “Bullish on Laurus Labs with a target price of ₹1085. The recommendation is to buy the stock.” | Choice Institutional Equities AnalysisChoice Institutional Equities | Laurus Labs | HIT | ||||
| “Recommends buying Laurus Labs at ₹934, targeting ₹1000, with a stop loss at ₹900. This is a breakout stock pick for toda…” | Sumeet BagadiaChoice Equity Broking | Laurus Labs | HIT | ||||
| “Recommends buying Laurus Labs at ₹900, targeting ₹945, with a stop loss at ₹880. This is based on a stock-specific appro…” | Vaishali ParekhPrabhudas Lilladher | Laurus Labs | NOT TRIGGERED | ||||
| “Recommends buying Laurus Labs Ltd. at around ₹923.25, with a stop loss at ₹891 for a target price of ₹988. The stock exh…” | Sumeet BagadiaChoice Equity Broking | Laurus Labs | MISS | ||||
| “Bullish on Laurus Labs Limited, recommending a buy between ₹915–930 with a target price of ₹1,030 in two to three months…” | Marketsmith India AnalysisMarketsmith India | Laurus Labs | MISS | ||||
| “Bullish on Laurus Labs, recommending a buy with a target price of ₹970 and a stop loss at ₹862. The stock has formed a b…” | Chandan TapariaMotilal Oswal Financial Services Ltd | Laurus Labs | MISS | ||||
| “Recommends buying Laurus Lab at ₹834 with a target of ₹860 and a stop loss at ₹820.” | Vaishali ParekhPrabhudas Lilladher | Laurus Labs Ltd | HIT | ||||
| “Retains a 'Buy' rating on Laurus Labs with a revised target price of ₹1,025. The brokerage raised earnings estimates for…” | Choice Institutional Equities AnalysisChoice Institutional Equities | Laurus Labs | HIT | ||||
| “Recommends buying Laurus Labs Ltd (LAURUSLABS) around ₹778.30, targeting ₹810 with a stop loss at ₹750. The stock displa…” | Sumeet BagadiaChoice Equity Broking | Laurus Labs | NOT TRIGGERED | ||||
| “Recommends buying Laurus Labs Ltd around ₹776, setting a stop loss at ₹748 and a target price of ₹838. The stock exhibit…” | Sumeet BagadiaChoice Equity Broking | Laurus Labs | HIT | ||||
| “Bullish on Laurus Labs for the short term, expecting a move towards ₹800 after consolidating near its support zone and b…” | Riyank AroraMehta Equities | Laurus Labs | PENDING | ||||
| “Bullish on Laurus Labs for the next two to three weeks, targeting ₹805 and ₹820 with a stop loss at ₹685. The stock is i…” | Hardik MataliaChoice Broking | Laurus Labs | PENDING | ||||
| “Recommends buying Laurus Labs with a target of ₹630 and a stop loss at ₹590 for short-term traders.” | Kunal BothraIndependent | Laurus Labs | HIT | ||||
| “Recommends buying Laurus Labs with a target of Rs 600 and a stop loss at Rs 540 for a short-term trading horizon.” | Kunal BothraIndependent | Laurus Labs | HIT | ||||
| “Bullish on Laurus Labs, recommending a buy above ₹585 with a stop loss at ₹570 and targets between ₹625-640. Steady buyi…” | Raja VenkatramanNeoTrader | Laurus Labs | MISS | ||||
| “Recommends buying Laurus Labs above ₹585 with a stop loss at ₹570 and targets of ₹625-640 for March 13. Steady buying at…” | Raja VenkatramanNeoTrader | Laurus Labs | MISS | ||||
| “Recommends buying Laurus Labs at ₹566 with a stop loss at ₹545 for a target price of ₹590. A notable bullish reversal pa…” | Ganesh DongreAnand Rathi | Laurus Labs | HIT | ||||
| “Recommends buying Laurus Labs with a target of ₹590 and a stop loss at ₹545 for a short-term trading horizon.” | Nooresh MeraniIndependent | Laurus Labs | MISS | ||||
| “Bullish on Laurus Lab, recommending a buy at ₹617 with targets of ₹645-665 and a stop loss at ₹584. The stock has broken…” | Ankush BajajIndependent | Laurus Labs Ltd | MISS | ||||
| “Bullish on Laurus Lab, recommending a buy at ₹617 with targets between ₹645-665 and a stop loss at ₹584. The stock has b…” | Ankush BajajIndependent | Laurus Labs Ltd | MISS | ||||
| “Retains 'Sell' rating on Laurus Labs with a price target of ₹475. The brokerage notes that while management did not offe…” | Goldman Sachs AnalysisGoldman Sachs Group Inc. | Laurus Labs | MISS | ||||
| “KR Choksey recommends accumulating Laurus Labs with a target price of ₹687. The call implies a bullish outlook on the st…” | Deven Choksey Research AnalysisDeven Choksey Research | Laurus Labs | PENDING | ||||
| “Recommends buying Laurus Labs with a target of ₹646 and a stop loss at ₹575 for a short-term trading horizon.” | Aakash HindochaNuvama Professional Clients Group | Laurus Labs | MISS | ||||
| “Bullish on Laurus Labs Ltd, recommending a buy above ₹587 with a target of ₹620 and a stop loss at ₹572. The stock found…” | Raja VenkatramanNeoTrader | Laurus Labs | MISS | ||||
| “Recommends buying Laurus Labs above ₹587, with a stop loss at ₹572 and a target of ₹620. The stock has found strong supp…” | Raja VenkatramanNeoTrader | Laurus Labs | MISS | ||||
| “Bullish on Laurus Labs Ltd, recommending a buy at ₹617 with targets of ₹645-665 and a stop loss at ₹584. The stock has b…” | Ankush BajajIndependent | Laurus Labs | MISS | ||||
| “Bullish on Laurus Labs, recommending a buy at ₹602 with targets of ₹680-705 and a stop loss at ₹555. The pharma and heal…” | Ankush BajajIndependent | Laurus Labs | MISS | ||||
| Call | Analyst | Instrument | Verdict | Actions |
|---|---|---|---|---|
| “Reiterated a 'Sell' rating on Laurus Labs, revising the target price upward to ₹775 from ₹750. Despite strong Q2FY26 res…” | Goldman Sachs AnalysisGoldman Sachs Group Inc. | Laurus Labs | — | |
| “Bullish on Laurus Labs, which is in a strong uptrend, forming higher tops and bottoms. The stock has decisively surpasse…” | Rajesh PalviyaAxis Securities | Laurus Labs | — | |
| “Maintains a 'Hold' rating on Laurus Labs, revising its target price to ₹850 from ₹640. The brokerage believes the curren…” | InCred Equities AnalysisInCred Equities | Laurus Labs | — | |
| “Recommends buying Laurus Labs shares for a target price of ₹885, with a stop loss at ₹810. The stock is in an overall up…” | Chandan TapariaMotilal Oswal Financial Services Ltd | Laurus Labs | — | |
| “Revised rating to 'Hold' on Laurus Labs with a target price of ₹639, valuing the company at 37x FY27 EPS. Anticipates be…” | Choice Institutional Equities AnalysisChoice Institutional Equities | Laurus Labs | — | |
| “Bullish on Laurus Labs Ltd, recommending to buy, hold, and accumulate the stock. It is trending higher within an 'Up-Slo…” | Rajesh PalviyaAxis Securities | Laurus Labs | — |
About Laurus Labs Limited
Laurus Labs Limited, together with its subsidiaries, manufactures and sells medicines and active pharmaceutical ingredients (APIs) in India and internationally. The company offers Generics APIs and solid oral drug products for intermediates for anti-retroviral (ARV), anti-diabetic, cardiovascular, anti-asthma, ophthalmology, oncology, and gastroenterology. It also develops and manufactures animal-origin-free recombinant proteins and cell-culture media supplements and research and development services, including drug substance development, drug product development, and biologics development. In addition, the company offers non-human ingredients; rare disease therapeutics; and finished dosages. Laurus Labs Limited was incorporated in 2005 and is based in Hyderabad, India.
Details
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
CEO
Dr. Satyanarayana Chava M.Sc., Ph.D.
Headquarters
Hyderabad
Employees
7,059
Website
lauruslabs.comExchange
View on NSE ↗Key stats
Market cap
₹1.26 L Cr
P/E ratio (TTM)
93.8
Dividend yield
0.09%
EPS (TTM)
₹24.78
Beta (1Y · daily vs NIFTY 50)
0.73
Beta (5Y · monthly vs NIFTY 50)
0.97
Shares float
36.59 Cr
EPS · quarter ended Sept 2026
₹8.16
Upcoming earnings
22 Jan 2027
Financial Performance
01 · Financials
02 · Earnings Per Share (EPS)
03 · Dividend Profile
Growth compares completed fiscal-year dividend totals on the company's own calendar: April–March (Indian FY), taken from its reported period-ends. Payout ledger: NSE corporate actions.
04 · Operating Efficiency (Growth Rates)
Balance-sheet-based
05 · Capital Structure & Asset Utilization
Asset turnover needs a prior year of assets — omitted for the earliest available year.
06 · Asset Base Composition
07 · Debt Level & Coverage
08 · Profit & Loss
Annual
| Line item | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|
| ₹4,813.51 Cr | ₹4,935.57 Cr | ₹6,040.55 Cr | ₹5,040.83 Cr | ₹5,553.96 Cr | ₹6,812.90 Cr | |
EBITDA | ₹1,574.34 Cr | ₹1,437.73 Cr | ₹1,598.19 Cr | ₹803.84 Cr | ₹1,130.38 Cr | ₹1,832.66 Cr |
| ₹983.82 Cr | ₹827.52 Cr | ₹790.11 Cr | ₹160.55 Cr | ₹358.32 Cr | ₹888.79 Cr | |
Diluted EPS | ₹18.28 | ₹15.35 | ₹14.64 | ₹2.97 | ₹6.64 | ₹16.45 |
09 · Balance Sheet
Annual
| Line item | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|
| ₹5,751.00 Cr | ₹6,968.00 Cr | ₹7,660.00 Cr | ₹8,387.00 Cr | ₹9,336.00 Cr | ₹10,511.00 Cr | |
| — | — | ₹2,015.09 Cr | ₹2,577.40 Cr | ₹2,763.73 Cr | ₹2,518.48 Cr | |
Stockholders' equity | ₹2,597.00 Cr | ₹3,351.00 Cr | ₹4,038.00 Cr | ₹4,111.00 Cr | ₹4,473.00 Cr | ₹5,300.00 Cr |
Current assets, Trade receivables, Cash & equivalents, Non-current assets, CWIP, Others, Total debt, Long-term debt, Current (short-term) debt have filed figures for only some of the years shown — the missing years are left blank rather than estimated.
Annual only — the data source doesn’t publish quarterly balance-sheet detail for most NSE-listed companies.
10 · Cash Flow Statement
Annual
| Line item | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|
| ₹733.00 Cr | ₹911.00 Cr | ₹994.00 Cr | ₹666.00 Cr | ₹602.00 Cr | ₹1,624.00 Cr | |
Investing cash flow | ₹-940.99 Cr | ₹-914.34 Cr | ₹-996.06 Cr | ₹-822.42 Cr | ₹-681.72 Cr | ₹-1,088.66 Cr |
| ₹255.00 Cr | ₹30.00 Cr | ₹-27.00 Cr | ₹250.00 Cr | ₹39.00 Cr | ₹-525.00 Cr | |
Capital expenditure | ₹-689.00 Cr | ₹-877.00 Cr | ₹-990.00 Cr | ₹-678.00 Cr | ₹-641.00 Cr | ₹-1,070.00 Cr |
End cash position | ₹48.46 Cr | ₹75.35 Cr | ₹45.67 Cr | ₹138.94 Cr | ₹99.54 Cr | ₹112.66 Cr |
Annual only — the data source has no quarterly cash-flow-statement coverage.
11 · Shareholding Pattern
NSE, quarterly
| Line item | Sep 21 | Dec 21–Sep 22(4Q) | Dec 22–Sep 23(4Q) | Dec 23–Mar 24(2Q) | Jun 24–Sep 24(2Q) | Dec 24–Mar 25(2Q) | Jun 25–Sep 25(2Q) | Dec 25–Mar 26(2Q) | Jun 26 |
|---|---|---|---|---|---|---|---|---|---|
| Promoter | 27.30% | 27.27% | 27.20% | 27.19% | 27.18% | 27.62% | 27.59% | 27.49% | 27.47% |
| Public | 72.70% | 72.73% | 72.80% | 72.81% | 72.82% | 72.38% | 72.41% | 72.51% | 72.53% |
| Employee trusts | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Source: NSE quarterly shareholding-pattern filings, collapsed to periods where the reported percentages held steady — a column spanning several quarters means no change was filed across them. No FII/DII sub-split available from this source — Public includes all non-promoter, non-employee-trust holders.
12 · Peer Comparison
Healthcare
| Company | ||||||||
|---|---|---|---|---|---|---|---|---|
| Sun Pharmaceutical Industries Limited | ₹4.25 L Cr | ₹1,769.9 | 38.8 | 5.09 | 13.7% | 0.06 | +11.9% | +3.7% |
| Divi's Laboratories Limited | ₹2.66 L Cr | ₹10,037.5 | 90.8 | 15.85 | 15.3% | 0.00 | +12.3% | +47.5% |
| Torrent Pharmaceuticals Limited | ₹1.79 L Cr | ₹4,738.5 | 79.4 | 21.31 | 25.8% | 1.79 | +21.5% | +32.5% |
| Laurus Labs Limited | ₹1.27 L Cr | ₹2,348 | 94.8 | 23.94 | 16.8% | 0.48 | +22.0% | +146.2% |
| Apollo Hospitals Enterprise Limited | ₹1.23 L Cr | ₹8,599.5 | 58.8 | 12.95 | 20.5% | 0.90 | +15.7% | +10.1% |
| Zydus Lifesciences Limited | ₹1.19 L Cr | ₹1,188.1 | 26.7 | 4.40 | 18.6% | 0.46 | +18.4% | +22.3% |
| Lenskart Solutions Limited | ₹1.16 L Cr | ₹689.7 | 181.4 | 13.30 | 5.6% | 0.35 | +35.4% | — |
| Dr. Reddy's Laboratories Limited | ₹1.14 L Cr | ₹1,374 | 40.6 | 3.02 | 11.4% | 0.21 | +3.2% | +14.5% |
| Cipla Limited | ₹1.13 L Cr | ₹1,402 | 38.9 | 3.27 | 11.3% | 0.02 | +2.1% | -6.7% |
| Mankind Pharma Limited | ₹1.03 L Cr | ₹2,475 | 45.9 | 6.31 | 11.7% | 0.39 | +17.0% | +3.1% |
| Aurobindo Pharma Limited | ₹98,101.93 Cr | ₹1,705 | 26.6 | 2.59 | 9.2% | 0.21 | +6.4% | +48.4% |
| Lupin Limited | ₹92,244.53 Cr | ₹2,008.6 | 16.7 | 4.11 | 23.8% | 0.29 | +23.9% | +0.6% |
Ranked by market cap within Healthcare, same metrics as the Fundamentals screener. Click a column to sort.
Official documents linked from their sources — offer documents as filed with SEBI (sebi.gov.in), annual reports and earnings-call transcripts as published on BSE (bseindia.com) and NSE (nseindia.com). Links open the source's own hosting; nothing is re-hosted here.
Oyster Renewable Invests INR 372 Crore In 60.9 MW Wind-Solar Hybrid Project For Laurus Labs In Andhra Pradesh
SolarQuarter · 5 days ago